Development of new anti-HER2 drugs and wide adaptation of the policy of continuing HER2 blockade beyond progression allowed for improvement of outcomes among advanced HER2 positive breast cancer patients, including prolongation of overall survival (allowing for achievement of median OS extending over 60 months [PERUSE]) and improvements in quality of life, at the expense of acceptable treatment toxicity. The gene discussed is ERBB2; the disease is breast cancer.